MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Pliant Therapeutics, Inc. (NASDAQ: PLRX)*
Organization & Developments: Pliant
Parents
Pliant Therapeutics, Inc. (NASDAQ: PLRX)*
Children
*Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States.
2022: Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
2022: Pliant Therapeutics: Wait For More Data Clarity On Dose-Dependent Response In FVC_ seekingalpha.com
2023: Pliant Therapeutics' Multi-Pronged Fibrosis Play (NASDAQ:PLRX)
2024: Pliant Therapeutics: Targeting Idiopathic Pulmonary Fibrosis_seekingalpha.com
Jumps
Finance & Acquisitions: Pliant
Key People: Pliant